Answers are grounded in this paper and cite their sources.
Randomized controlled trial finds dienogest better for symptom control in adenomyosis, while LNG-IUS reduces uterine volume.
Background: Adenomyosis, a common gynecological condition in reproductive-aged women, causes dysmenorrhea, menorrhagia, and pelvic pain, significantly affecting quality of life. Hormonal therapies like LNG-IUS and dienogest offer uterus-preserving treatment options. Objectives: To compare the clinical efficacy, symptom control, and adverse effect profile of oral dienogest versus levonorgestrel-releasing intrauterine device (LNG-IUS) in the management of adenomyosis. Methods: Arandomized controlled trial (RCT) was conducted on 100 women diagnosed with adenomyosis. Participants were randomly divided into two groups: oral dienogest (2 mg daily) and LNG-IUS (Mirena), and followed up at 3, 6, and 12 months. VAS scores, PBAC scores, uterine volume, and adverse effects were analyzed. Results: Dienogest showed superior reduction in pain and menstrual volume at 6 and 12 months. LNG-IUS was more effective in reducing uterine volume. Irregular bleeding and device expulsion were higher with LNG-IUS. Conclusion: Dienogest demonstrated better long-term symptom control and tolerability, making it a favorable conservative option for adenomyosis.
No takes yet. Share an insight, caveat, or question.
Johari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: